Recommended

GSK appoints new CEO
New webinar | Addressing the time-to-result challenge posed by short shelf-life radiopharmaceuticals, register today
Genmab acquires biotech Merus for $8bn
US FDA licensing first for IL-23 inhibitor to treat paediatric psoriasis
Teva makes progress on API business divestment
Takeda to move away from cell therapy
news

Lonza to enhance commercial antibody-drug conjugate supply capacity

2
SHARES

A new cGMP filling line is set to be built at Lonza’s Stein site in Switzerland, expanding filling capacity and enabling the handling and filling of bioconjugates for commercial supply.

Lonza to enhance commercial antibody-drug conjugate supply capacity

Credit: Taljat David / Shutterstock.com

Lonza is planning to build a commercial-scale aseptic current good manufacturing practice (cGMP) filling line at its site in Stein, Switzerland. The new filling line will facilitate the aseptic filling of highly-potent antibody drug conjugates (ADCs) and lyophilisation under containment. The added capabilities will increase Lonza’s capacity to support clinical and commercial supply of bioconjugates.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

Further details of the ADC filling line agreement

Under an extended customer agreement, construction of the new line will enable commercial supply of these products. It builds upon an existing partnership based to the manufacturing of highly-potent payloads, drug-linker and conjugation services, and the large-scale supply of monoclonal antibodies (mAbs).

“The new dedicated cGMP commercial line in Stein will complement Lonza’s global manufacturing network and will further strengthen our capabilities within Drug Product Services, encompassing drug product formulation and analytical development, and early-launch, clinical filling and commercial filling,” Peter Droc, Head of Drug Product Services at Lonza commented.

The new filling line is projected to be operational in 2027. Approximately 115 new jobs are expected to be created.

Enhancing manufacturing capabilities

The bioconjugates market is currently valued at $33 billion according to research by Lonza. The ADC market is valued at $10 billion. The ADC market is expected to grow at a compound annual growth rate (CAGR) of 20 percent between 2023 and 2028, the contract development and manufacturing organisation (CDMO) highlighted.

Announcement a new ADC filling line signifies another milestone for Lonza. It follows completion of a new filling line in Visp, at the end of March 2023, which was created to add capacity and capabilities for cGMP clinical and commercial drug product manufacturing. When the news was announced, Lonza stated the first batches were planned to be fulfilled in April 2023.

Additionally, the CDMO announced in January 2023 that it had marked the groundbreaking of a large-scale commercial filling facility in Stein. This was funded investment of approximately £455 million.

Lonza completes bioconjugation facility expansion

Share via
Share via